Home Top Movers CoherusBioSciences, Inc. (CHRS) Stock on the Rise Following Success of JUPITER-02 Pivotal...

CoherusBioSciences, Inc. (CHRS) Stock on the Rise Following Success of JUPITER-02 Pivotal Study

CoherusBioSciences, Inc. (CHRS) stock prices were up by 3.53% shortly after market trading commenced on June 4th, 2021, bringing the price per share up to USD$13.50 early on in the trading day.

JUPITER-02 Results

The company recently announced the successful results from its pivotal study, JUPITER-02, which was a randomized, double-blind, placebo-controlled Phase 3 clinical trial. The trial was designed to evaluate toripalimub in conjunction with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC)

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Interim Analysis

The interim analysis reported the meeting of the study’s primary endpoint, thereby demonstrating a progression-free survival (PFS) that showed statistically significant and clinically meaningful improvement as compared to chemotherapy alone. The study also met its secondary endpoints of PFS, as assessed by the assigned investigator, and objective response rate (ORR) data assessed by BIRC.

Results of the Analysis

Duration of response exhibited longer times and there was a higher disease control rate, as well as higher one- and two-year survival rates or the arm of the study that was administered toripalimab. The safety profile of the company’s treatment consolidated previous findings that established its safety in the clinical trials for toripalimab.

ASCO 2021

ASCO 2021 saw more than 30 abstracts for toripalimab bring accepted, two of which were selected for oral presentations. These abstracts describe the antitumor activities derived from observations of various cancers of the nasopharynx, skin, lung, esophagus, stomach, liver, biliary duct, head and neck, and pancreas. Pertinently, ten of the abstracts accepted indicated CHRS’s treatment’s potential in perioperative, adjuvant, or neoadjuvant treatment settings.

Scope of Toripalimab

Concurrent with the conducting of the JUPITER-02 trial, the annual ASCO meeting will see the presenting of various other studies of toripalimab. These results will support the existing development strategy, such as perioperative immunotherapy in patients who are found to have multiple solid tumors, including mucosal melanoma, esophageal cancer, gastric cancer, liver cancer, and non-small cell lung cancer. Furthermore, the results will facilitate the exploration of toripalimab for the treatment of ICC, checkpoint inhibitors for which have not yet been approved for use.

Future Outlook for CHRS

Armed with the success of its positive topline data and reaching primary and secondary endpoints, CHRS is poised to capitalize on the gain in momentum to push for the commercialization of the treatment. Current and potential investors are hopeful that the management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Here’s why Soligenix, Inc. (SNGX) stock is Popping High today

Soligenix, Inc. (SNGX) stock gained Pediatric Investigation Plan (PIP) waiver for HyBryte™ (SGX301 or hypericin) by European Medicines Agency (EMA) after which the SNGX...

Clover Health Investments Corp. (CLOV) stock rises during pre-market. Let’s find out why?

Clover Health Investments Corp. (NASDAQ: CLOV) stock declined by 23.61% at last close while the CLOV stock price gains by 5.73% in the pre-market...

GameStop Inc. (GME) stock plunged during after-hour session. Here’s the update

GameStop Inc. (NASDAQ: GME) stock gained by 0.85% at the last close while the GME stock price declines by 5.21% in the after-hours session....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam